Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non‐obese diabetes mice
Microbial Biotechnology · 2023-04 · 16 (4) · 813-826
DOI: 10.1111/1751-7915.14200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 30.12.2022. Verfasst von Ruiya Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Abelmoschus, Gastrointestinal Microbiome, Diabetes Mellitus. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Pharmaceutical University, University-Industry Cooperation Research Project in Jiangsu, National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Huangkui capsule (HKC), a traditional Chinese medicine, has been used for medication of kidney diseases, including diabetic nephropathy (DN). The current study aimed to evaluate the effects of HKC in the modulation of gut microbiota and the amelioration of metabolite levels by using non‐obese diabetes (NOD) mice with DN. The microbiota from three parts of intestines (duodenum, ileum and colon) in NOD mice with and without HKC treatment were analysed using 16S rDNA sequencing techniques. Untargeted metabolomics in plasma of NOD mice were analysed with liquid mass spectrometry. Results showed that HKC administration ameliorated DN in NOD mice and the flora in duodenum were more sensitive to HKC intervention, while the flora in colon had more effects on metabolism. The bacterial genera such as Faecalitalea and Muribaculum significantly increased and negatively correlated with most of the altered metabolites after HKC treatment, while Phyllobacterium , Weissella and Akkermansia showed an opposite trend. The plasma metabolites, mainly including amino acids and fatty acids such as methionine sulfoxide, BCAAs and cis‐7‐Hexadecenoic acid, exhibited a distinct return to normal after HKC treatment. The current study thereby provides experimental evidence suggesting that HKC may modulate gut microbiota and subsequently ameliorate the metabolite levels in DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
- Suzhong Pharmaceutical Research Institute, Nanjing, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
ORCID-Profile: Jie Wu
Förderung
- China Pharmaceutical University
- University-Industry Cooperation Research Project in Jiangsu
- National Natural Science Foundation of China
Zitieren
APA
Shi, R., Tao, Y., Tang, H., Wu, C., Fei, J., Ge, H., Gu, H. F., & Wu, J. (2023). Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non‐obese diabetes mice. Microbial Biotechnology, 16(4), 813-826. https://doi.org/10.1111/1751-7915.14200
Vancouver
Shi R, Tao Y, Tang H, Wu C, Fei J, Ge H, et al. Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non‐obese diabetes mice. Microbial Biotechnology. 2023;16(4):813-826. doi:10.1111/1751-7915.14200
BibTeX
@article{Shi2023,
author = {Shi, Ruiya and Tao, Yingjun and Tang, Haitao and Wu, Chenhua and Fei, Jingjin and Ge, Haitao and Gu, Harvest F and Wu, Jie},
title = {Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non‐obese diabetes mice},
journal = {Microbial Biotechnology},
year = {2023},
volume = {16},
number = {4},
pages = {813--826},
doi = {10.1111/1751-7915.14200}
}
EUVIMED